Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Possible Goal for New Tuberculosis-Vaccine Identified

Published: Monday, July 08, 2013
Last Updated: Monday, July 08, 2013
Bookmark and Share
A new study shows for the first time the essential role of the molecule SOCS3 in the control of Tuberculosis.

This could have impact on the future development of a vaccine.

Tuberculosis is sometimes perceived as a feared killer of the past but is still a dreadful disease of mankind. One third of the world population is infected with the bacteria Mycobacterium tuberculosis that causes the disease. However, Tuberculosis is manifested only in approximately 10 percent of those infected. Still, about 2 million Tuberculosis patients die every year worldwide.

Mycobacterium tuberculosis multiplies inside white blood cells known as macrophages. In infected people who don't develop the Tuberculosis, the immune system either the bacteria or impairs bacterial multiplication. The exact mechanisms behind this are not known in detail, hampering the development of effective vaccines and treatments of the disease. Why the disease is manifested in some individual, but not in others, is not completely understood.

The recent study shows that a molecule called SOCS3 is required for control of the infection. The discovery was done using an experimental infection of mice genetically modified so that they do not express SOCS3 in different immune cells. These mice were dramatically susceptible to the infection with Mycobacterium tuberculosis.

"Like a soldier with two guns the molecule SOCS3 engages in different ways in the combat against Mycobacterium tuberculosis. We were stunned by the fact that the same molecule independently controls diverse mechanisms in different cell types," says Martin Rottenberg, from the Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet.

The control of Tuberculosis is hampered by the appearance of antibiotic-resistant strains. Moreover, the Tuberculosis vaccine, developed almost 100 years ago, shows low efficiency against the most common pulmonary disease. An improved understanding of how our immune responses control the infection might be used for the design of new vaccines.

"We speculate that SOCS3 could be a new target for vaccines to improve the protection against Tuberculosis," says Martin Rottenberg.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

New Hope for Setback-dogged Cancer Treatment
Researchers at Karolinska Institutet announce breakthrough in the study of how IGF-1 receptor-binding antibodies can help those with cancer.
Wednesday, November 28, 2012
Scientific News
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
COPD Linked to Increased Bacterial Invasion
Persistent inflammation in COPD may result from a defect in the immune system that allows airway bacteria to invade deeper into the lung.
Finding Factors That Protect Against Flu
A clinical trial examining the body’s response to seasonal flu suggests new approaches for evaluating the effectiveness of seasonal flu vaccines.
Vaccinations Are More Effective When Administered In The Morning
Research from the University of Birmingham shows that influenza vaccinations have more protective responses when administered in the morning.
Secrets of a Deadly Virus Family Revealed
Scripps Research scientists uncover the glycoprotein structure of LCMV. The findings could guide development of treatments for Lassa fever.
Cytokine Triggers Immune Response at Expense of Blood Renewal
Research highlights promise of Anti-IL-1 drugs to treat chronic inflammatory disease.
Reduced Immune Response Causes Flu Deaths in Older Adults
Yale study suggests that immune response to flu causes death in older people, not the virus.
Exposure To Routine Viruses Makes Mice Better Test Subjects
Study shows that infections make mouse immune system act more like that in humans.
Immune Booster Tested in Advanced Merkel Cell Cancer
The immunotherapy drug produced durable responses in many patients.
Factors Influencing Influenza Vaccine Effectiveness Uncovered
The long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited, new research suggests.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!